financetom
Business
financetom
/
Business
/
BRIEF-Epsium Enterprise Sees U.S. IPO Of 1 Million Ordinary Shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Epsium Enterprise Sees U.S. IPO Of 1 Million Ordinary Shares
Jun 25, 2024 2:14 PM

June 25 (Reuters) - Epsium Enterprise:

* EPSIUM ENTERPRISE LTD - EXPECT THE INITIAL PUBLIC OFFERING

PRICE

WILL BE BETWEEN $5.00 AND $7.00 PER ORDINARY SHARE

* EPSIUM ENTERPRISE LTD SEES U.S. IPO OF 1 MILLION ORDINARY

SHARES

- SEC FILING

* EPSIUM ENTERPRISE LTD SAYS EF HUTTON LLC IS NOW THE

UNDERWRITER

FOR U.S. IPO

* EPSIUM ENTERPRISE LTD - RESALE SHAREHOLDERS ARE OFFERING

1.2

MILLION ORDINARY SHARES IN AGGREGATE TO BE SOLD IN OFFERING

PURSUANT TO RESALE PROSPECTUS

Source text for Eikon:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
This Chinese Personal Care Brand Soars Nearly 140% In Pre-Market After Announcing Combined Entity With Plutonian Acquisition
This Chinese Personal Care Brand Soars Nearly 140% In Pre-Market After Announcing Combined Entity With Plutonian Acquisition
Jun 10, 2024
Big Tree Cloud saw its stock soar nearly 140% in pre-market trading on Monday, following the announcement of a business combination with Plutonian Acquisition Corp. ( DSY ) According to their recent press release, the shares and warrants of the newly combined entity began trading on Nasdaq under the tickers “DSY” and “DSYWW”, respectively, on June 7, 2024. See Also:...
Skye Bioscience to discontinue development of eye disease treatment
Skye Bioscience to discontinue development of eye disease treatment
Jun 10, 2024
June 10 (Reuters) - Skye Bioscience ( SKYE ) said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study. ...
ProKidney Reports 'Positive Interim Results' for Potential Chronic Kidney Disease Treatment
ProKidney Reports 'Positive Interim Results' for Potential Chronic Kidney Disease Treatment
Jun 10, 2024
07:22 AM EDT, 06/10/2024 (MT Newswires) -- ProKidney ( PROK ) said its phase 2 REGEN-007 trial of rilparencel as a potential treatment for chronic kidney disease caused by diabetes yielded positive interim results. The ongoing trial includes diabetes patients with chronic kidney disease. In one group, patients with at least 12 months follow-up showed stabilized kidney function for 18...
Apple's Worldwide Developers Conference 2024 Opens Monday
Apple's Worldwide Developers Conference 2024 Opens Monday
Jun 10, 2024
07:19 AM EDT, 06/10/2024 (MT Newswires) -- Apple ( AAPL ) is set to open its week-long Worldwide Developers Conference 2024 Monday, where it plans to present new software, technologies, and platform updates. Sources familiar with the matter told The Wall Street Journal that the company is also expected to announce new artificial intelligence features and form new partnerships for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved